Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)

Launched by INSTITUT CURIE · Sep 26, 2022

Keywords

ClinConnect Summary

The IMMUNO-TET trial is a research study looking into thymic epithelial tumors (TETs), which are a type of cancer that affects the thymus gland. The main goal of this trial is to understand the immune system's response to these tumors and to gather information about the genetic features of patients with localized TET. This information may help doctors learn more about the disease and improve treatment options in the future.

To be a part of this trial, you need to be at least 18 years old and have a suspected localized thymic epithelial tumor. You should not have received any treatment for this cancer yet and must be scheduled for surgery to remove the tumor. If you choose to participate, you will help researchers gather important information that could benefit future patients. The study is currently recruiting participants, and anyone interested should discuss it with their healthcare provider to see if they meet the eligibility criteria and can give informed consent.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient with suspicion of localised thymic epithelial tumour.
• • 2. Age ≥ 18 years.
• • 3. Treatment-naïve patient for this disease.
• • 4. Patient with an indication for thymectomy and thymomectomy in one of the partner centers.
• • 5. Signed informed consent form of the patient.
• Exclusion Criteria:
• • 1. Neoadjuvant chemotherapy.
• • 2. No social security affiliation.
• • 3. Person under legal protection.
• • 4. Other neoplasia in progress or cured within the last 3 years (except for operated carcinoma in situ).